Vinita Bali Reappointed As Additional Director Of Syngene International; Vijaya Chandru Joins As Independent Director
Syngene International Limited has reappointed Vinita Bali as an Additional Non-Executive Director for one year, effective July 22, 2026.
Further, the company has appointed Vijaya Chandru and Arun Chandavarkar as Additional Independent Directors, effective April 29, 2026, subject to shareholder approval and regulatory compliance.
Bali served as Chief Executive Officer and Managing Director (CEO & MD) of Britannia Industries from 2005 to 2014. Her earlier roles include positions at The Coca-Cola Company and Cadbury Schweppes across markets, including the UK, Nigeria, South Africa, the United States, and Chile. She currently serves as a Non-Executive Director at SATS Ltd. and Cognizant Technology Solutions, and is on the Board of Bajaj Auto Ltd. At Syngene International, Bali is part of the Nomination and Remuneration Committee, Audit Committee, and Corporate Social Responsibility (CSR) Committee. She has worked in the consumer goods sector and corporate leadership roles.
Chandru has co-founded companies including CrisprBits Pvt. Ltd., Strand Life Sciences, PicoPeta Simputers, and Yantri Labs. He has held academic roles at the Indian Institute of Science, the National Centre for Biological Sciences, and the Harvard T.H. Chan School of Public Health. He was named a Fellow by the American Association for the Advancement of Science in 2024 and was recognised by the World Economic Forum (WEF) in 2006. He works in research, technology, and entrepreneurship. His work includes areas such as computational biology, optimisation, and decision sciences. Chandru holds a PhD in Operations Research from the Massachusetts Institute of Technology.
Chandavarkar is a former CEO of Biocon Ltd., where he served until November 2019. During his tenure, he was involved in the company’s public listing in 2004, partnerships in biologics, and investments in research and infrastructure. He also oversaw restructuring initiatives and the divestment of the enzymes business. He has served in industry bodies, including the Confederation of Indian Industry, and is associated with companies such as Biocon Biologics and Mynvax. Chandavarkar holds a B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay (IIT-B) and a PhD from the Massachusetts Institute of Technology.
